Company: CERO
Filing Date: 2025-12-05
Form Type: S-1
Source: 0001213900-25-118817
Chunk: 411

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-12-05
Form: S-1
Chunk 411
---
 of common stock, net of any shares assumed to have been purchased with the proceeds, using
the treasury stock method. In periods for which the Company reports a net loss, the common stock equivalents are not included, as they
would be anti-dilutive.

The following table summarizes the number of shares of Common Stock
issuable upon conversion or exercise, as applicable, of convertible securities, stock options, and warrants that were not included in
the calculation of diluted net loss per share because such shares are anti-dilutive:

|                                                                                           |     | December 31, |        |     | December 31, |     |
|                                                                                           |     |         2024 |        |     |         2023 |     |
|                                                                                           |     |   -Successor |        |     | -Predecessor |     |
| Conversion of convertible preferred stock issued and outstanding                          |     |              | 53,740 |     |              | 900 |
| Conversion of convertible preferred stock underlying convertible preferred stock warrants |     |              |  8,185 |     |              |  60 |
| Exercise of public warrants and common warrants into common stock                         |     |              | 13,193 |     |              |   - |
| Common stock underlying outstanding options (2024 Plan)                                   |     |              |  3,247 |     |              |  25 |
|                                                                                           |     |              | 78,365 |     |              | 985 |

Restricted common stock can
be issued to directors, executives or employees of the Company and are subject to time-based vesting. These potential shares are excluded
from the computation of basic loss per share as these shares are not considered outstanding until vested. No unvested restricted common
stock awards were issued or outstanding during the years ended December 31, 2024 or 2023.

NOTE 5 – PROPERTY AND EQUIPMENT

Property and equipment, net, consisted of the
following as of December 31, 2024 and 2023:

|                                |     | 2024        
 (Successor) | December 31, |   |     | 2023          
 (Predecessor) | December 31, |   |
|:-------------------------------|:----|:------------|-------------:|:--|:----|:--------------|-------------:|:--|
| Laboratory equipment           |     | $           |    2,507,839 |   |